ReviewOne health (Amsterdam, Netherlands)2026
An overview of HPAI H5N1 clade 2.3.4.4b and its emerging threat in mainland Australia: Identified knowledge gaps.
Review in One health (Amsterdam, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluation of the implementation of the One Health approach in Guinea: Application of the NEOH framework to decentralized One Health platforms.One health (Amsterdam, Netherlands) · 2026Article
- Genomic and Clinicopathological Characterization of a Reassortant HPAI H5N1 (Clade 2.3.4.4b) in an Endangered Cinereous Vulture (Aegypius monachus) in South Korea, 2026.Transboundary and emerging diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The highly pathogenic avian influenza (HPAI) H5N1 virus, particularly clade 2.3.4.4b, is currently causing a panzootic. The threat of its incursion into mainland Australia is escalating, especially following its detection in Antarctica and recently on Australia's sub-Antarctic territory, Heard Island. Comprehensive research on this emerging risk remains limited, partly due to ongoing rapid genomic mutations and evolving epidemiological dynamics. This review provides an in-depth analysis of clade 2.3.4.4b H5N1 and highlights critical knowledge gaps that must be addressed to mitigate the potential threat to mainland Australia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.